eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium 2023 Annual Meeting, taking place from December 5 – 9, 2023 in San Antonio, Texas. eFFECTOR plans to discuss the results of the clinical trial and provide further updates on zotatifin development at the conference. Presentation details can be found below.
Abstract Title: Phase 1/2 Dose Expansion Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in Patients with ER+ Metastatic Breast Cancer
At the time of presentation, eFFECTOR’s poster will be made available on the “Publications & Presentations” page of the “Science” section of its website.
About eFFECTOR Therapeutics
Interesting LPWAN Solutions
The Future of Workspace â€“ Emerging Realities and Approaches for â€œThe Officeâ€
Keynote Presentation by Vodafone